Evidence map›Paper›PMID 41264124›Full record

ArticleMolecular biology reports2025

Anti-tumor effects of GPC3 CAR-iNKT cells in murine models of hepatocellular carcinoma.

Zixuan Wang, Guangji Zhang

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Zixuan WangBeijing Institute of Biological Products Co., Ltd, Beijing, 100176, China.
Guangji ZhangChinese Institutes for Medical Research, Beijing, China. zhangguangji@cimrbj.ac.cn.

Funding

Beijing Municipal Human Resources and Social Security Bureau 2021-ZZ-004
6 · The paper itself

Abstract

Glypican-3 (GPC3) has been identified as a compelling target for immunotherapy against hepatocellular carcinoma (HCC), owing to its selective expression on tumor cells. Chimeric antigen receptor invariant natural killer T (CAR-iNKT) cells have emerged as an innovative alternative to CAR-T cells, offering potential advantages for allogeneic applications in cellular therapy. In this study, we engineered GPC3-targeted CAR-iNKT cells and demonstrated their specific cytotoxic activity against GPC3-positive HCC cells in vitro. Using a murine HCC model, we further validated that GPC3 CAR-iNKT cells effectively suppressed tumor progression and enhanced survival outcomes. Pharmacokinetic studies showed favorable persistence of CAR-iNKT cells in vivo, with low off-target toxicity observed in critical organs. Collectively, these preclinical findings suggest that GPC3 CAR-iNKT cells may provide a safe and effective therapeutic option for HCC, warranting further investigation in clinical trials.

Indexed as

Carcinoma, HepatocellularGlypicansImmunotherapy, AdoptiveLiver NeoplasmsNatural Killer T-CellsReceptors, Chimeric AntigenAnimalsCell Line, TumorDisease Models, AnimalHumansMiceXenograft Model Antitumor AssaysGlypicansGPC3 protein, humanReceptors, Chimeric AntigenCAR-iNKT cellsGPC3Hepatocellular carcinomaImmunotherapy

Identifiers

PMID41264124

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.